Global Typhoid Antibody Testing Market 2025 – 2034

Reports Description

As per the Typhoid Antibody Testing Market conducted by the CMI Team, the global Typhoid Antibody Testing Market is expected to record a CAGR of 11.48% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 1.31 Billion. By 2034, the valuation is anticipated to reach USD 3.49 Billion.

Overview

Typhoid antibody testing, which is essential for early identification and treatment of typhoid fever, has quickly developed as a result of increasing waterborne disease outbreaks, low sanitation levels in developing countries, and an enhanced awareness of the need for early disease identification. Healthcare professionals and diagnostic manufacturers have focused on the development of reliably cost-effective antibody testing kits to improve their test offerings while continuing to meet the increasing rate of diagnostic tests requested.

North America and Europe continue to be the dominant market providers given the advanced healthcare systems and the increased education and awareness of the use of diagnostic tests. The Asia-Pacific region is developing as a notable growth market given the high disease burden, increased healthcare spending and access to disease diagnostic testing. There is still work being done on the point of care test device launch with more funding for government initiatives targeting infectious diseases and statements from public health organizations for increased public health campaigns. Typhoid antibody testing is now part of the global disease surveillance and management of patients.

Key Trends & Drivers                                                                                                  

The Typhoid Antibody Testing Market Trends present significant growth opportunities due to several factors:

• Increasing Prevalence of Typhoid in Developing Countries: The global typhoid antibody testing market is expected to expand significantly due to the rising prevalence of typhoid in developing and underdeveloped countries. South Asia and Africa currently account for the highest number of reported cases, largely driven by rapid population growth, lack of access to safe drinking water, and limited availability of hygienic food sources. According to a 2023 report by the United Nations (UN) and UNESCO, nearly 26% of the global population still lacks access to safe, germ-free water, while around 46% live in areas with poorly managed sanitation systems. Water pollution remains a critical factor behind this growing health challenge, with contributors including industrial discharge, oil spills, mining and construction activities, agricultural runoff, and urban waste. Rising consumerism further aggravates these pressures, amplifying the risk of waterborne diseases such as typhoid and driving demand for reliable antibody testing solutions.

• Rising Collaborative Efforts to Develop Innovative Testing and Vaccination Tools: Firms involved with the typhoid antibody testing industry are forming strategic collaborations to improve disease management and expand their product development pipelines. These partnerships are not limited to diagnostics but also include the development of innovative vaccine and delivery technologies to augment antibody testing that can strengthen preventive healthcare systems. For Instance, in August 2023, Vaxxas and SK Bioscience announced a collaboration to develop a new combination product that includes a vaccine-delivery device. In this collaboration, Vaxxas will apply its high-density microarray patch (HD-MAP) platform to enhance vaccine delivery, access, and patient adherence, and SK Bioscience will provide its own proprietary typhoid vaccine. These alliances are projected to drive innovation, expand product presence within the market, and provide solutions that, when netted together, enhance the overall revenue potential of the global typhoid antibody testing industry.

Significant Threats

The Typhoid Antibody Testing Market has several major threats that may hinder growth and profitability now and, in the future, including:

• Lack of Awareness and Accessibility in Remote Areas: Although the global typhoid antibody testing market faces a strong outlook, market growth can be stymied in part by a lack of awareness of testing capabilities especially in rural and remote areas. In many underdeveloped settings, communities may not have access to appropriate healthcare systems and diagnostics or educational programs to provide community members with knowledge of the causes, risks, and treatments for typhoid fever. Advanced testing may not be utilized in settings where the greatest burden of disease exists. Testing can cost money and may deter patients from lower socioeconomic statuses from acting promptly on their calls for diagnosis increasing the potential for delay in care and for persistence of disease within these communities. Factors such as the absence of outreach programs, education campaigns provided by the government, and general involvement of NGOs in health education can compound these barriers. Affordable testing solutions, awareness directed towards patients within the community, and more equitable access to health and community health education programs will be required to mitigate some of these barriers that exist and to promote population-based equity in the growth of the global typhoid antibody testing market.

Opportunities

• Increased Focus on Preventive Healthcare: The global transition to preventive healthcare presents a significant growth opportunity for the typhoid antibody testing market. As awareness of the health and economic value of early disease detection builds, governments and people are prioritizing preventive measures over morally dubious reactive treatments. In terms of focus areas for preventive efforts which can prevent thousands of deaths each year, typhoid fever is a waterborne infectious disease with a high prevalence in low- and middle-income countries. Antibody testing enables early diagnoses which provides the timely treatment necessary to limit the incidence of severe complications and reduce the likelihood of disease transmission at the community level. Moreover, the increasing burden of infectious disease and the cost of hospital care have further reinforced the value proposition for screening programs in non-hospital settings, particularly in areas of high disease risk like South Asia and Sub-Saharan Africa. Healthcare providers, NGOs, and multinational health organizations are increasingly promoting routine antibody testing as part of prevention care packages. The increased focus on wellbeing and disease prevention is expected to continue to raise the level of demand for more reliable, affordable, and accessible typhoid antibody testing worldwide.

Category Wise Insights

By Product Type

• Rapid Serological Tests: Rapid serology tests continue to be among the most widely used categories of products due to rapid tests, low cost, and accessibility. They are especially advantageous in resource-limited areas with limited access to more advanced diagnostic technologies. Overall utility, ease of use, turnaround time, and low infrastructure needs have made them popular for mass screenings and outbreak control.

• Typhoid Test: The Typhidot test has increased in use for its relatively higher accuracy in detecting typhoid-specific antibodies. Typhidot is frequently used in hospital and clinical settings which prioritize confidence in tests that are being used for diagnosis. Typhidot has the unique ability to differentiate the IgM and IgG antibody isotypes which aids in both early diagnosis and in following disease progression, and is therefore an important diagnostic test for physicians to use.

• Widal Test: The Widal test, which is one of the oldest diagnostic methods for typhoid, continues to remain a widely used diagnostic method if not at least in rural and low-income countries. Its low cost, easy accessibility, and overall familiarity keep the demand relatively high compared to newer methods that have improved accuracy. Many healthcare providers in limited resource countries particularly still rely on Widal tests because they are low-cost and can be delivered fairly simply.

By End User

• Hospitals: Hospitals are a primary end-user segment owing to their provision of comprehensive patient diagnosis and treatment. As patient hospitalization rises for fever and infectious diseases, hospitals have shown increased reliance on antibody testing in support of clinical decision making. These facilities also allow for specialization and use of qualified professional staff to use antibody testing options and ensure better uptake in the end-user category.

• Serological Testing Centers: Specialized serological testing centers conduct mass screening, as well as large-scale disease surveillance programs. They are especially prominent in regions with high typhoid incidence to process high volumes of samples quickly. Their specialized nature in antibody based diagnostic testing helps increase the accuracy of diagnostic testing and supports epidemiological data collection and disease management strategies.

• Clinics: Clinics are the first facility accessed for patients presenting with typhoid symptoms. The demand for cheap, rapid antibody tests, mainly in the rural and semi-urban area clinics, is strong as a quick diagnosis and initiation of treatment are needed. Clinics are significantly increasing the uptake of cost-effective testing strategies.

• Diagnostic Centers: Diagnostic centers accommodate testing for both individual patients and hospitals, making it easy for patients to access and trust results for typhoid antibody tests. Another variable leading to growing demand in this segment is the popularity of stand-alone diagnostic labs, particularly in urban areas.

• Others: The “others” segment includes government lab programs, research facilities, or NGOs working in public health. They represent an important component of awareness campaigns, mass screening programs, and pilot programs to provide new diagnostics. Their significance may be higher as an intermediate testing program associated with unavailable health care infrastructure in underdeveloped areas.

Historical Context

At first, the typhoid antibody testing market was a small and niche diagnostic method that was relatively unknown outside endemic areas and had very few possibilities for technological advancements. There was little global acceptance or demand, and tests were largely limited to small labs or geographic diagnosis centers with no international standardization. Nevertheless, within the last few decades, typhoid antibody testing has established itself as a major platform for infectious disease diagnostics, with a global uptick in awareness, public health infrastructure, and the clear need for rapid and reliable detection in both developed and developing nations.

New immunoassay technologies, rapid test formats, and automated platforms helped transfer typhoid antibody testing from typically being a region-specific niche testing method to an acceptable global diagnostic method. Today, diagnostic multinationals, specialist biotech companies, and regional manufacturers provide a wide range of testing formats (rapid lateral flow assay to complex ELISA based formats) that support a range of clinical and public health methods, ensuring global access and market relevance.

Impact of Recent Tariff Policies

Recent tariff policies are increasingly serving as a disruptive force in the typhoid antibody testing market by reshaping cost structures, supply chains, and competitive dynamics. Many countries are imposing increased duties on imported medical diagnostics or components (e.g., reagents, test strips, assay kits, lab equipment), which cause manufacturers who depend on cross-border supply chains to experience rising costs of input and finished product. Import tariffs in the United States, one of the largest markets for in vitro diagnostics (IVD), now include a baseline reciprocal tariff on IVD produced elsewhere in the world, including tests and test components.

Producers based in regions with lower manufacturing capacity, for example in parts of Asia, Africa, and Latin America, may face lower margins or require price increases to end-users (e.g., clinics, hospitals, and public health programs). Tariff-induced cost increases also risk delaying adoption of newer, more sensitive or rapid typhoid antibody tests in lower income settings with already tight budgets. To reduce some of these pressures, some market players are shifting manufacturing away from lower-cost locations and closer to demand centres to avoid high import duties or redesigning product components to qualify under lower tariff schedules or local content rules.

Report Scope

Regional Analysis

The Typhoid Antibody Testing Market is segmented by key regions and includes detailed analysis across major countries. Below is a brief overview of the market dynamics in each country:

North America: North America is the largest region in the worldwide typhoid antibody testing market, due to a sophisticated healthcare structure, high per capita healthcare expenditure, and awareness related to preventive diagnostics. Increased global travel and immigrants from endemic regions drive increased demand for testing. With a strong research and development portfolio, a proactive approach to novel testing technology and a research and development sector that has an overwhelming presence with testing distribution throughout hospitals, clinics, and diagnostic labs it is saturated in hospitals, clinics, and diagnostic labs, and there is a relatively strong demand for testing.

• US: In the U.S. with a strong healthcare structure and sophistication in technology diagnostics, there has always been a strong push for and emphasis on early detection of infectious agents. A high degree of awareness, considerable government recommended vaccination for typhoid fever, and an increasing number of people traveling from endemic regions generate substantial demand for testing. With leading diagnostic manufacturing companies in the unitized states with dedication to research and development the public should benefit from effective blood testing for typhoid antibody response.

• Canada: The typhoid antibody testing market in Canada benefits from increased public awareness, government supported public health initiatives focusing on preventive care, and the availability and access to sophisticated diagnostic procedures. The country has a multicultural population, facilitating the travel of people from endemic regions for testing. Favorable reimbursement policies assist with diagnostics, and the access and availability of wait times to get to diagnostic centers in either urban or semi-urban locations provide consistent growth in this region of the testing population.

Europe: Europe holds a large portion of the global typhoid antibody testing market due to strong public health care systems, comprehensive disease surveillance networks, and growing travel from endemic regions. Increased awareness of infections while traveling, recommendations for government screening, and advancements in diagnostic testing technologies that support the market to expand. Regional access to laboratories and point-of-care testing also drive regional growth.

• Germany: Germany is the leading country in Europe due to strong healthcare systems, advanced diagnostic laboratories, and a strong focus on infectious disease surveillance. High outbound travel for Germans to move to destinations in Asia and Africa promotes testing for typhoid. Additionally, strong supportive healthcare funding, early adoption of advanced diagnostics, and partnerships with biotech firms have promoted a continuous expansion in the market.

• UK: The UK market is driven by rising awareness of infections while traveling, increased immigration from typhoid endemic countries and government-funded vaccination and screening programs. A well-developed diagnostic network and robust integration of public/private healthcare systems ensure access to antibody testing. An increase in funding to point of care testing technologies, as well as research and development partnerships with diagnostic companies promotes market growth.

• France: Leading diagnostic hospitals and laboratories make things even easier for patients to access the facility and for normal patients as well. Along with public education campaigns, the increase in rapid diagnostic kits and increasing preventative screening for travelers and immigrant communities also support the demand for antibody testing.

Asia-Pacific: Continued government immunization campaigns, increased awareness around diagnosis, and population demand for affordable testing solutions will also contribute to the market’s growth across the region. Additionally, rising healthcare expenditure, increased medical tourism, and increased investment into diagnostic technology will also positively drive the potential market within the region due to typhoid antibody testing.

• Japan: Japan’s market growth is supported by its advanced healthcare infrastructure, increased adoption of new diagnostic devices, and government-led schemes to monitor and test for infectious diseases. In addition, increased international travel and an aging local population further increase the need for preventive testing. In addition, the emphasis on high-quality, accurate diagnostic techniques promotes overall self-taken testing adoption in hospitals, research institutions, and private clinics.

• China: China is a significant market due to its high population, persistent urbanization, and increased rates of infectious diseases. There is a high adoption rate due to increased government investments in healthcare and advances in diagnostic infrastructure in urban spaces. Moreover, increasing public health-based initiatives, high disposable income, and demand for rapid and affordable test kits are accelerating market growth and expansion.

• India: Increasing healthcare spending, government-led immunizations and screening programs, and increased public awareness of testing all drive testing demand. The presence of domestic manufacturers of diagnostic kits in addition to rapidly increasing supply to rural and urban usage further increases rates of adoption and overall growth in India.

LAMEA: The typhoid antibody testing market is developing at a steady pace within the LAMEA region, driven by improved public health efforts, expanded tourism and trade, and gradual improvement in access to healthcare. In addition to government disease surveillance programs, international partnerships among health authorities in the region, combined with the availability of low-cost testing kits, are critical for growth, especially in blue-chip markets and developing economies.

• Brazil: Growth of the Brazilian market for evaluating typhoid infection testing for antibodies has been significantly driven in the past years by increased awareness of infectious diseases, improving healthcare infrastructure, and rapidly rising demands in travel-related testing. Government-led health initiatives and private sector healthcare investments are also improving access to testing. Demand for affordable testing and the implementation of public healthcare testing laboratories has continued to support steady growth in adoption of typhoid antibody testing across Brazil.

• South Africa: In South Africa, the establishment of good lab capacity for testing, as well as recurrent outbreaks of typhoid fever contribute to increasing market demand. A renewed government commitment to disease monitoring and preventive healthcare has supported market expansion. Improved access to diagnostic testing centers, international aid programs for vacant centers operating in the region, and the development of rapid testing kits for typhoid fever have increased the overall utility of testing, likely with greater uptake in urban populations of South Africa.

Key Developments

The Typhoid Antibody Testing Market has undergone a number of important developments over the last couple of years as participants in the industry look to expand their geographic footprint and enhance their product offering and profitability by leveraging synergies.

• In January 2025, CTK Biotech launched The OnSite Typhoid IgG/IgM Combo Rapid Test. This is a lateral flow immunoassay for the detection and differentiation of IgG and IgM anti-Salmonella typhi (S. typhi) and paratyphi in human serum, plasma or whole blood. The antibody detection test is a noninvasive diagnostic method that can be performed within 15 minutes by minimally skilled personnel and does not uselaboratory equipment.

• In April 2023, Vanguard Diagnostics launched India’s first Typhoid RT PCR test based on patented technology. The test was developed in collaboration with Graphic Era University in Dehradun. The patented method is the first of its type in India and represents a great example of collaboration between academia and industry.

These activities have allowed the companies to further develop their product portfolios and sharpen their competitive edge to capitalize on the available growth opportunities in the Typhoid Antibody Testing Market.

Leading Players

The Typhoid Antibody Testing Market is moderately consolidated, dominated by large-scale players with infrastructure and government support. Some of the key players in the market include:

• Abbott Laboratories
• Diagnostic BioSystems
• Siemens Healthineers
• BD (Becton Dickinson and Company)
• HoffmannLa Roche
• Thermo Fisher Scientific
• Hycult Biotech
• Bio-Rad Laboratories
• Medmix
• Zhejiang Dian Diagnostics
• Meridian Bioscience
• Creative Diagnostics
• BioMérieux
• InBios International
• DiaSorin
• Grifols
• Adaltis
• Others

Typhoid antibody testing has a moderately concentrated market with competition among multinational diagnostic companies, specialty biotechnology companies, and regional competitors. Global market leaders such as Abbott Laboratories, Siemens Healthineers, BD (Becton Dickinson and Co.), F. Hoffmann-La Roche, Thermo Fisher Scientific, Bio-Rad Laboratories, and BioMérieux hold leading positions with large diagnostic portfolios, established distribution channels, and established reputations for infectious disease testing. In addition to leading competitors, a growing number of regional competitors, including Zhejiang Dian Diagnostics, InBios International, Adaltis, Hycult Biotech, Creative Diagnostics, Meridian Bioscience, and Diagnostic BioSystems, are entering the market with new test kits, inexpensive tests, and growing market share in regional markets, especially in Asia Pacific and LAMEA (Latin America, the Middle East, and Africa). Together, these established competitors and new emerging competitors are driving competing forces in the landscape of testing with improved access to testing, innovation, and improved uptake of typhoid testing in the market around the globe.

The Typhoid Antibody Testing Market is segmented as follows:

By Product Type

• Rapid Serological Tests
  • Hem-agglutination & Co-agglutination
  • Counter Immunoelectrophoresis
• Typhidot Test
• Widal Test

By End-User

• Hospitals
• Serological Testing Centers
• Clinics
• Diagnostic Centers
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America